Radical prostatectomy (RP) is a common primary treatment choice for patients with low- and intermediate-risk prostate cancer (PCa) [1], while monitoring prostate-specific antigen (PSA) levels after surgery has been a standard approach for detecting any possible biochemical recurrence (BCR) [2]. This evidence concerns the gene KLK3 and prostate carcinoma.